CRIS Current Research Information System

PALLADINI, ARIANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.628
AS - Asia 3.435
EU - Europa 2.391
AF - Africa 222
SA - Sud America 142
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.825
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.569
VN - Vietnam 1.191
CN - Cina 880
SG - Singapore 765
IT - Italia 628
GB - Regno Unito 467
DE - Germania 288
HK - Hong Kong 204
SE - Svezia 200
FR - Francia 132
IN - India 122
RU - Federazione Russa 116
BR - Brasile 102
NL - Olanda 94
UA - Ucraina 89
CH - Svizzera 77
IE - Irlanda 76
CI - Costa d'Avorio 72
ZA - Sudafrica 61
JP - Giappone 59
KR - Corea 51
FI - Finlandia 48
TG - Togo 45
CA - Canada 43
EE - Estonia 35
BG - Bulgaria 32
BE - Belgio 27
PH - Filippine 22
ID - Indonesia 20
AR - Argentina 18
TH - Thailandia 18
LT - Lituania 14
JO - Giordania 13
RO - Romania 13
AT - Austria 12
MX - Messico 12
TW - Taiwan 12
EG - Egitto 11
IQ - Iraq 11
PL - Polonia 11
SC - Seychelles 10
TR - Turchia 10
BD - Bangladesh 9
PK - Pakistan 9
EC - Ecuador 8
SA - Arabia Saudita 7
CO - Colombia 6
HR - Croazia 6
NG - Nigeria 6
AU - Australia 5
DK - Danimarca 5
MA - Marocco 5
AE - Emirati Arabi Uniti 4
CL - Cile 4
ES - Italia 4
GR - Grecia 4
DO - Repubblica Dominicana 3
IR - Iran 3
LB - Libano 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
GH - Ghana 2
KE - Kenya 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
LI - Liechtenstein 2
MN - Mongolia 2
MY - Malesia 2
PS - Palestinian Territory 2
TN - Tunisia 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BJ - Benin 1
BO - Bolivia 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
SN - Senegal 1
ZM - Zambia 1
Totale 9.825
Salva come PNG Salva come JPEG
Città #
Singapore 537
Ashburn 413
Fairfield 392
Southend 370
Chandler 328
Ho Chi Minh City 268
Hanoi 233
Hong Kong 196
Houston 176
Shanghai 174
Woodbridge 172
Wilmington 170
Ann Arbor 158
Bologna 150
San Jose 145
Seattle 145
Dong Ket 132
Cambridge 130
Santa Clara 116
Hefei 103
Beijing 100
Princeton 93
Dublin 76
Abidjan 72
Council Bluffs 71
Bern 70
Boardman 65
Lauterbourg 52
Jacksonville 49
Lomé 45
Tokyo 44
Los Angeles 43
Milan 41
Seoul 39
Westminster 39
Bremen 37
Dallas 37
Nanjing 37
Helsinki 36
Da Nang 35
Haiphong 35
Padova 33
Berlin 32
Sofia 32
Guangzhou 31
New York 30
Jinan 28
Redmond 26
Brussels 25
Frankfurt am Main 25
Redwood City 24
Buffalo 23
Redondo Beach 21
Saint Petersburg 21
Casalecchio di Reno 20
Johannesburg 20
Tianjin 20
Falkenstein 19
London 19
Hải Dương 18
Ottawa 18
San Diego 18
Changsha 17
Jakarta 17
Turin 17
Amsterdam 16
Shenyang 15
São Paulo 15
Hebei 14
Toronto 14
Amman 13
Biên Hòa 13
Des Moines 13
Phoenix 13
Jiaxing 12
Nanchang 12
Ha Long 11
Zhengzhou 11
Bengaluru 10
Mülheim 10
Lappeenranta 9
Montreal 9
Moscow 9
Quận Bình Thạnh 9
Vienna 9
Atlanta 8
Bến Tre 8
Can Tho 8
Delhi 8
Vicenza 8
Barnet 7
Bühl 7
Bắc Giang 7
Chieti 7
Crocetta 7
Kerpen 7
Ningbo 7
Poplar 7
Shijiazhuang 7
Warsaw 7
Totale 6.525
Salva come PNG Salva come JPEG
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 427
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 380
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 337
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 317
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 264
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 245
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 244
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases 232
Virus-like particle display of HER2 induces potent anti-cancer responses 229
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 226
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 212
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 209
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 209
Cancer immunoprevention: from mice to early clinical trials 203
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 201
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 200
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 196
In silico modeling and in vivo efficacy of cancer preventive vaccinations 196
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 195
ImmunoGrid: Towards agent-based simulations of the human immune system at a natural scale 193
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 191
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 190
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 187
Antimetastatic activity of a preventive cancer vaccine. 185
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis 184
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 184
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 184
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 184
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 182
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine 178
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes? 176
Modeling the competition between lung metastases and the immune system using agents. 175
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 175
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 175
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 173
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 170
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 169
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. 162
Translational immunomics of cancer prevention. 161
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 160
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 159
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 158
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma 156
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy 150
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 144
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer 143
Computational models as novel tools for cancer vaccines. 139
ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design, and optimization 130
Mathematical and computational models in tumor immunology 126
Predictive models in tumor immunology. 90
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature 71
Development of cellular models expressing cynomolgus (Macaca fascicularis) HER2 for the functional evaluation of cross-reactive anti-human HER2 response 69
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC 41
Totale 10.036
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.522
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.522
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021350 0 0 0 0 0 0 0 0 0 44 43 263
2021/20221.005 102 47 83 38 99 70 29 54 52 66 223 142
2022/20231.261 132 154 67 183 75 99 44 66 180 54 103 104
2023/2024490 25 45 22 32 29 50 25 209 7 19 11 16
2024/20251.409 102 166 112 75 230 78 101 68 9 115 82 271
2025/20263.161 484 323 242 230 315 173 293 104 727 270 0 0
Totale 10.036